Table 8.
Country of publication and information discussed regarding the influenza vaccine.
| Information Regarding Influenza Vaccine | Country of Publication | Available, n (%) |
Unavailable, n (%) |
OR (95% CI) a | p |
|---|---|---|---|---|---|
| Benefits of the vaccine | Spain | 6 (10.2) | 10 (24.4) | 0.32 (0.10–0.99) | 0.044 |
| United States of America | 8 (13.6) | 3 (7.3) | 1.43 (0.35–5.90) | 0.625 | |
| Others/Unknown | 2 (3.4) | 5 (12.2) | 0.21 (0.04–1.19) | 0.060 | |
| Hispanic American countries | 43 (72.9) | 23 (56.1) | 1 | ||
| Adverse effects of the vaccine | Spain | 8 (20.5) | 8 (13.1) | 1.75 (0.58–5.26) | 0.319 |
| United States of America | 5 (12.8) | 6 (9.8) | 1.46 (0.40–5.29) | 0.567 | |
| Others/Unknown | 2 (5.1) | 5 (8.2) | 0.7 (0.13–3.89) | 0.684 | |
| Hispanic American countries | 24 (61.5) | 42 (68.9) | 1 | ||
| Recommendations for pregnancy b | Spain | 4 (9.8) | 12 (20.3) | 0.33 (0.09–1.14) | 0.073 |
| United States of America | 4 (9.8) | 7 (11.9) | 0.57 (0.15–2.14) | 0.405 | |
| Others/Unknown | 0 (0) | 7 (11.9) | - | 0.012 | |
| Hispanic American countries | 33 (80.5) | 33 (55.9) | 1 | ||
| Recommendations for children c | Spain | 0 (0) | 16 (23.9) | - | 0.000 |
| United States of America | 1 (3.0) | 10 (14.9) | 0.11 (0.01–0.88) | 0.015 | |
| Others/Unknown | 0 (0) | 7 (10.4) | - | 0.015 | |
| Hispanic American countries | 32 (97.0) | 34 (50.7) | 1 | ||
| Recommendations for people aged 60/65 or older | Spain | 4 (10.5) | 12 (19.4) | 0.33 (0.09–1.14) | 0.073 |
| United States of America | 1 (2.6) | 10 (16.1) | 0.1 (0.01–0.83) | 0.012 | |
| Others/Unknown | 0 (0) | 7 (11.3) | - | 0.012 | |
| Hispanic American countries | 33 (86.8) | 33 (53.2) | 1 | ||
| Recommendations for people with chronic lung diseases | Spain | 2 (9.5) | 14 (17.7) | 0.38 (0.08–1.85) | 0.219 |
| United States of America | 1 (4.8) | 10 (12.7) | 0.27 (0.03–2.24) | 0.198 | |
| Others/Unknown | 0 (0) | 7 (8.9) | - | 0.114 | |
| Hispanic American countries | 18 (85.7) | 48 (60.8) | 1 | ||
| Recommendations for people with chronic cardiovascular disease | Spain | 2 (10.0) | 14 (17.5) | 0.38 (0.08–1.85) | 0.219 |
| United States of America | 0 (0) | 11 (13.8) | - | 0.049 | |
| Others/Unknown | 0 (0) | 7 (8.8) | - | 0.114 | |
| Hispanic American countries | 18 (90.0) | 48 (60.0) | 1 | ||
| Recommendations for people with cancer | Spain | 1 (7.1) | 15 (17.4) | 0.27 (0.03–2.25) | 0.203 |
| United States of America | 0 (0) | 11 (12.8) | - | 0.109 | |
| Others/Unknown | 0 (0) | 7 (8.1) | - | 0.198 | |
| Hispanic American countries | 13 (92.9) | 53 (61.6) | 1 | ||
| Recommendations for people with obesity | Spain | 0 (0) | 16 (18.4) | - | 0.054 |
| United States of America | 0 (0) | 11 (12.6) | - | 0.109 | |
| Others/Unknown | 0 (0) | 7 (8.0) | - | 0.198 | |
| Hispanic American countries | 13 (100) | 53 (60.9) | 1 | ||
| Recommendations for healthcare workers | Spain | 3 (16.7) | 13 (15.9) | 0.79 (0.19–3.12) | 0.732 |
| United States of America | 0 (0) | 11 (13.4) | - | 0.080 | |
| Others/Unknown | 0 (0) | 7 (8.5) | - | 0.159 | |
| Hispanic American countries | 15 (83.3) | 51 (62.2) | 1 | ||
| Recommendations for people with HIV d | Spain | 0 (0) | 16 (17.6) | - | 0.194 |
| United States of America | 0 (0) | 11 (12.1) | - | 0.343 | |
| Others/Unknown | 0 (0) | 7 (7.7) | - | 0.586 | |
| Hispanic American countries | 9 (100) | 57 (62.6) | 1 | ||
| Recommendations for people with chronic kidney disease | Spain | 0 (0) | 16 (17.2) | - | 0.336 |
| United States of America | 0 (0) | 11 (11.8) | - | 0.584 | |
| Others/Unknown | 0 (0) | 7 (7.5) | - | 1.000 | |
| Hispanic American countries | 7 (100) | 59 (63.5) | 1 | ||
| Recommendations for people with diabetes mellitus | Spain | 2 (9.5) | 14 (17.7) | 0.38 (0.08–1.85) | 0.219 |
| United States of America | 1 (4.8) | 10 (12.7) | 0.27 (0.03–2.24) | 0.198 | |
| Others/Unknown | 0 (0) | 7 (8.9) | - | 0.114 | |
| Hispanic American countries | 18 (85.7) | 48 (60.8) | 1 | ||
| Recommendations for all people older than 6 months | Spain | 1 (9.1) | 15 (16.9) | 0.42 (0.05–3.59) | 0.421 |
| United States of America | 1 (9.1) | 10 (11.2) | 0.63 (0.07–5.56) | 0.679 | |
| Others/Unknown | 0 (0) | 7 (7.9) | - | 0.300 | |
| Hispanic American countries | 9 (81.8) | 57 (64.0) | 1 | ||
| Costs of the vaccine | Spain | 1 (5.6) | 15 (18.3) | 0.19 (0.02–1.57) | 0.093 |
| United States of America | 0 (0) | 11 (13.4) | - | 0.058 | |
| Others/Unknown | 0 (0) | 7 (8.5) | - | 0.128 | |
| Hispanic American countries | 17 (94.4) | 49 (59.8) | 1 | ||
| Description of the dosage | Spain | 0 (0) | 16 (18.6) | - | 0.054 |
| United States of America | 1 (7.1) | 10 (11.6) | 0.41 (0.05–3.48) | 0.402 | |
| Others/Unknown | 0 (0) | 7 (8.1) | - | 0.198 | |
| Hispanic American countries | 13 (92.9) | 53 (61.6) | 1 | ||
| Hoaxes and conspiracy theories | Spain | 6 (31.6) | 10 (12.4) | 6.0 (1.61–22.34) | 0.004 |
| United States of America | 4 (21.0) | 7 (8.6) | 5.71 (1.29–25.29) | 0.031 | |
| Others/Unknown | 3 (15.8) | 4 (4.9) | 7.5 (1.35–41.72) | 0.036 | |
| Hispanic American countries | 6 (31.6) | 60 (74.1) | 1 |
a OR (95% CI): odds ratio (95% confidence interval). b Recommendations for pregnancy (from 13 weeks of gestation or in any trimester of pregnancy). c Recommendations for children of 6 months to 2/5/6/10 years. d HIV: human immunodeficiency virus.